PHILADELPHIA, Jan. 11, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (NASDAQ: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., Chairman & CEO of Echo Therapeutics, will present at Noble Financial Capital Markets’ Eighth Annual Equity Conference.
Dr. Mooney will make a presentation to prospective corporate partners and investors on Tuesday, January 17th at 12:30 PM ET. The Company’s presentation will be delivered at the Hard Rock Hotel in Hollywood, Florida.
At the time of the presentation, a live audio and high-definition video webcast of Echo Therapeutics’ presentation and a copy of the presentation materials will be available on the Company’s website www.echotx.com on the Events page or through the Noble Financial websites: www.noblefcm.com or http://www.BOCEM2012.com. Echo Therapeutics recommends registering at least 10 minutes prior to the start of the presentation to ensure timely access. A Microsoft SilverLight viewer (a free download from the presentation link) is required to participate. The webcast and presentation will also be archived on www.echotx.com for 30 days following the event.
About Echo Therapeutics
Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.
For More Information:
Christine Olimpio
Director, Investor Relations & Corporate Communications
(215) 717-4104
Connect With Us:
- Visit our website at www.echotx.com
- Follow us on Twitter at www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotx
SOURCE Echo Therapeutics, Inc.
